Literature DB >> 30955817

Immunological and pathological effects of vitamin E with Fetomune Plus® on chickens experimentally infected with avian influenza virus H9N2.

Walaa F Awadin1, Abdelfattah H Eladl2, Reham A El-Shafei3, Mohamed A El-Adl4, Hanaa S Ali5.   

Abstract

Avian influenza virus (AIV) H9N2 infection causes economic losses on poultry farms, and immunostimulants are essential for improving chicken immunity. This study evaluated the immunological and pathological effects of vitamin E with Fetomune Plus® (a commercial product based on a yeast extract and vitamins) on chickens experimentally infected with AIV H9N2. Three groups of white Hy-Line chicks were included. The G1 group was kept as an uninfected untreated control, the G2 group was intranasally infected with the AIV H9N2 strain (0.5 ml of 106 50% egg infectious dose (EID50)), and the G3 group was infected and treated with vitamin E (200 mg/kg of diet) and Fetomune Plus® (1 ml/liter of drinking water) for four weeks. The gene expression of interferon-gamma (IFN-γ), interleukin (IL)-6, and IL-2 was determined at 3, 5 and 7 days post-infection (PI). Virus shedding titers and rates and haemagglutination inhibition (HI) antibody titers were detected. Clinical signs, mortalities and post-mortem lesions were recorded. The birds were weighed, and relative organ weights were calculated. Tissue specimens were taken for histopathological examination and immunohistochemistry (IHC). The expression of IFN-γ in the duodenum revealed a significant increase in G2 compared to G3 at 3 days PI, while the duodenal and splenic expression of IL-6 was significantly increased in G2 compared to G3 at 5 days PI. IL-2 was overexpressed in the duodenum in G3 compared to G2 at 3 and 5 days PI. A significant decrease (P ≤ 0.05) in the virus shedding titer and an increase in the HI titers were detected in G3 compared to G2. The clinical signs and the mortality rate were clearly appeared in G2 than in G3. By IHC, lower H9N2 staining intensity was observed in the examined organs from G3 than in those from G2. In conclusion, as a first report, vitamin E with Fetomune Plus® supplementation for four weeks could improve the immunological and pathological effects of H9N2 infection on chickens.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AIV H9N2; Chickens; Fetomune Plus(®); Gene expression; Histopathology; Immunohistochemistry; Vitamin E

Mesh:

Substances:

Year:  2019        PMID: 30955817     DOI: 10.1016/j.vetmic.2019.02.028

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  5 in total

1.  Biochemical and molecular effects of a commercial diuretic with herbal extract on experimentally induced urolithiasis in chickens.

Authors:  Mahmoud G El Sebaei; Reham A El-Shafei; Mohamed A El-Adl; Amany Farag; Abdelfattah H Eladl
Journal:  Vet Res Commun       Date:  2021-11-30       Impact factor: 2.459

2.  Quick and improved immune responses to inactivated H9N2 avian influenza vaccine by purified active fraction of Albizia julibrissin saponins.

Authors:  Hongxiang Sun; Liyan Fei; Binnian Zhu; Minghua Shi
Journal:  BMC Vet Res       Date:  2020-11-07       Impact factor: 2.741

3.  Changes in oxidation-antioxidation function on the thymus of chickens infected with reticuloendotheliosis virus.

Authors:  Dahan Yang; Chenhui Zhao; Meixi Zhang; Shujun Zhang; Jie Zhai; XueLi Gao; Chaonan Liu; Xiaoping Lv; Shimin Zheng
Journal:  BMC Vet Res       Date:  2020-12-11       Impact factor: 2.741

Review 4.  Dietary fiber in poultry nutrition and their effects on nutrient utilization, performance, gut health, and on the environment: a review.

Authors:  Rajesh Jha; Pravin Mishra
Journal:  J Anim Sci Biotechnol       Date:  2021-04-19

5.  Glycine Nano-Selenium Enhances Immunoglobulin and Cytokine Production in Mice Immunized with H9N2 Avian Influenza Virus Vaccine.

Authors:  Zhihua Ren; Samuel Kumi Okyere; Ming Zhang; Xin Zhang; Hongxuan He; Yanchun Hu
Journal:  Int J Mol Sci       Date:  2022-07-18       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.